CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Mind Medicine (MindMed) Inc. Subordinate Voting Shares - MNMD CFD

3.69
5.38%
Market Trading Hours* (UTC) Opens on Friday at 13:30

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 21:00 (UTC)
Min traded quantity 0.01
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Mind Medicine (MindMed) Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 3.9
Open* 3.84
1-Year Change* -44.91%
Day's Range* 3.66 - 3.84
52 wk Range 2.88-25.65
Average Volume (10 days) 13.99K
Average Volume (3 months) 419.73K
Market Cap 182.17M
P/E Ratio -100.00K
Shares Outstanding 38.60M
Revenue N/A
EPS -2.57
Dividend (Yield %) N/A
Beta 2.13
Next Earnings Date Aug 9, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Sep 21, 2023 3.69 -0.16 -4.16% 3.85 3.86 3.66
Sep 20, 2023 3.90 -0.06 -1.52% 3.96 4.05 3.77
Sep 19, 2023 4.01 0.02 0.50% 3.99 4.05 3.93
Sep 18, 2023 4.05 -0.09 -2.17% 4.14 4.15 4.01
Sep 15, 2023 4.15 -0.05 -1.19% 4.20 4.30 4.06
Sep 14, 2023 4.29 0.25 6.19% 4.04 4.32 4.03
Sep 13, 2023 4.04 -0.06 -1.46% 4.10 4.28 4.00
Sep 12, 2023 4.19 -0.09 -2.10% 4.28 4.49 4.17
Sep 11, 2023 4.28 0.37 9.46% 3.91 4.29 3.91
Sep 8, 2023 3.99 0.05 1.27% 3.94 3.99 3.85
Sep 7, 2023 3.91 -0.03 -0.76% 3.94 4.02 3.90
Sep 6, 2023 4.09 0.23 5.96% 3.86 4.10 3.85
Sep 5, 2023 3.95 0.02 0.51% 3.93 4.04 3.89
Sep 1, 2023 4.08 -0.09 -2.16% 4.17 4.29 4.07
Aug 31, 2023 4.13 0.28 7.27% 3.85 4.29 3.85
Aug 30, 2023 3.84 0.04 1.05% 3.80 3.95 3.80
Aug 29, 2023 3.85 0.13 3.49% 3.72 3.87 3.72
Aug 28, 2023 3.79 0.00 0.00% 3.79 3.95 3.78
Aug 25, 2023 3.79 -0.02 -0.52% 3.81 3.88 3.70
Aug 24, 2023 3.83 -0.20 -4.96% 4.03 4.06 3.81

Mind Medicine (MindMed) Inc. Subordinate Voting Shares Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2019
Total revenue 0 0 0 0 0
Total Operating Expense 66.331 93.854 33.03 1.10477 5.42921
Selling/General/Admin. Expenses, Total 30.162 59.065 14.399 0.456936 3.10517
Research & Development 32.969 34.789 18.631 2.04904
Depreciation / Amortization 3.2 0.006618 0.275
Interest Expense (Income) - Net Operating
Operating Income -66.331 -93.854 -33.03 -1.10477 -5.42921
Interest Income (Expense), Net Non-Operating 1.69 -0.445 -0.907 0 0.02751
Other, Net 7.845 0.106 0 -0.0725
Net Income Before Taxes -56.796 -94.193 -33.937 -1.10477 -5.47421
Net Income After Taxes -56.796 -93.036 -33.937 -1.10477 -5.47421
Net Income Before Extra. Items -56.796 -93.036 -33.937 -1.10477 -5.47421
Net Income -56.796 -93.036 -33.937 -1.10477 -5.47421
Income Available to Common Excl. Extra. Items -56.796 -93.036 -33.937 -1.10477 -5.47421
Income Available to Common Incl. Extra. Items -56.796 -93.036 -33.937 -1.10477 -5.47421
Diluted Net Income -56.796 -93.036 -33.937 -1.10477 -5.47421
Diluted Weighted Average Shares 30.8575 27.3785 17.7489 0.37943 6.92954
Diluted EPS Excluding Extraordinary Items -1.84059 -3.39815 -1.91206 -2.91167 -0.78998
Diluted Normalized EPS -1.84059 -3.39815 -1.91206 -1.22171 -0.78998
Unusual Expense (Income) 0.641219
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total revenue 0 0 0 0 0
Total Operating Expense 20.862 13.9 16.983 16.943 18.505
Selling/General/Admin. Expenses, Total 8.263 5.07 9.211 7.617 8.264
Research & Development 11.799 8.03 6.972 8.526 9.441
Operating Income -20.862 -13.9 -16.983 -16.943 -18.505
Interest Income (Expense), Net Non-Operating 1.232 1.153 0.498 -0.007 0.018
Other, Net -5.185 7.844 0 -0.007 0.036
Net Income Before Taxes -24.815 -4.903 -16.485 -16.957 -18.451
Net Income After Taxes -24.815 -4.903 -16.485 -16.957 -18.451
Net Income Before Extra. Items -24.815 -4.903 -16.485 -16.957 -18.451
Net Income -24.815 -4.903 -16.485 -16.957 -18.451
Income Available to Common Excl. Extra. Items -24.815 -4.903 -16.485 -16.957 -18.451
Income Available to Common Incl. Extra. Items -24.815 -4.903 -16.485 -16.957 -18.451
Diluted Net Income -24.815 -4.903 -16.485 -16.957 -18.451
Diluted Weighted Average Shares 38.0773 37.7314 29.2963 28.2434 28.1489
Diluted EPS Excluding Extraordinary Items -0.6517 -0.12994 -0.5627 -0.60039 -0.65548
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.6517 -0.12994 -0.5627 -0.60039 -0.65548
Depreciation / Amortization 0.8 0.8 0.8 0.8 0.8
Unusual Expense (Income)
  • Annual
  • Quarterly
2022 2021 2020 2019 2019
Total Current Assets 146.055 137.215 81.519 2.91521 6.73654
Cash and Short Term Investments 142.142 133.539 80.094 0.017801 3.01645
Cash & Equivalents 0.017801
Short Term Investments
Total Receivables, Net 0.005042
Prepaid Expenses 3.913 3.676 1.425 0.021357 0.0342
Total Assets 169.993 164.002 81.519 2.91521 11.9615
Property/Plant/Equipment, Total - Net 0
Other Long Term Assets, Total 0.331 0
Total Current Liabilities 17.892 10.408 3.008 0.143617 1.9612
Accounts Payable 2.111 4.178 2.022 0.143617 1.9612
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 19.076 12.338 5.651 0.19749 1.9612
Total Long Term Debt 0 0 0 0 0
Total Equity 150.917 151.664 75.868 2.71772 10.0003
Common Stock 0 0 5.51407 15.3218
Additional Paid-In Capital 344.758 288.29 120.22 0.792485
Retained Earnings (Accumulated Deficit) -194.468 -137.672 -44.636 -3.62328 -5.32143
Other Equity, Total 0.627 1.046 0.284 0.034436
Total Liabilities & Shareholders’ Equity 169.993 164.002 81.519 2.91521 11.9615
Total Common Shares Outstanding 37.9791 28.1022 20.96 0.40552 11.0999
Other Liabilities, Total 1.184 1.93 2.643 0.053873 0
Other Current Assets, Total 2.87101 3.6859
Cash 142.142 133.539 80.094 3.01645
Intangibles, Net 3.689 6.869 0 5.225
Goodwill, Net 19.918 19.918 0
Accrued Expenses 5.877 6.23 0.986
Other Current Liabilities, Total 9.904
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 132.413 146.055 156.51 109.09 123.227
Cash and Short Term Investments 129.409 142.142 154.519 105.741 120.472
Cash 129.409 142.142 154.519 105.741 120.472
Prepaid Expenses 3.004 3.913 1.826 3.172 2.755
Other Current Assets, Total 0.165 0.177
Total Assets 155.529 169.993 180.907 134.277 149.234
Property/Plant/Equipment, Total - Net
Goodwill, Net 19.918 19.918 19.918 19.918 19.918
Intangibles, Net 2.898 3.689 4.479 5.269 6.089
Total Current Liabilities 24.096 17.892 26.038 7.871 10.559
Accounts Payable 2.32 2.111 0.824 0.732 3.332
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 25.185 19.076 27.314 9.773 12.429
Total Long Term Debt 0 0 0 0 0
Deferred Income Tax
Total Equity 130.344 150.917 153.593 124.504 136.805
Common Stock 0 0 0 0 0
Additional Paid-In Capital 348.986 344.758 342.415 296.734 291.931
Retained Earnings (Accumulated Deficit) -219.283 -194.468 -189.565 -173.08 -156.123
Other Equity, Total 0.641 0.627 0.743 0.85 0.997
Total Liabilities & Shareholders’ Equity 155.529 169.993 180.907 134.277 149.234
Total Common Shares Outstanding 38.2901 37.9791 37.5411 28.4474 28.1615
Accrued Expenses 6.687 5.877 7.467 7.139 7.227
Other Liabilities, Total 1.089 1.184 1.276 1.902 1.87
Other Current Liabilities, Total 15.089 9.904 17.747
Other Long Term Assets, Total 0.3 0.331
  • Annual
  • Quarterly
2022 2021 2020 2019 2019
Net income/Starting Line -56.796 -93.036 -33.937 -1.10477 -5.47421
Cash From Operating Activities -50.139 -45.824 -23.597 -0.206066 -3.19971
Cash From Operating Activities 0.006618
Non-Cash Items 7.079 42.716 8.279 0.686323 0.0725
Changes in Working Capital -3.602 3.037 2.061 0.205774 1.927
Cash From Investing Activities 0 -0.297 0 -0.211048
Capital Expenditures -0.310361
Other Investing Cash Flow Items, Total 0 -0.297 0 0.099313
Cash From Financing Activities 59.051 98.824 96.704 0.285516 9.90205
Issuance (Retirement) of Stock, Net 59.458 98.824 97.099 0.285516 9.90205
Issuance (Retirement) of Debt, Net 0
Foreign Exchange Effects -0.309 0.742 0.284 -0.001382
Net Change in Cash 8.603 53.445 73.391 -0.132972 6.70234
Amortization 3.18 2.616 0 0.275
Deferred Taxes 0 -1.157 0
Financing Cash Flow Items -0.407 0 -0.395
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -24.815 -56.796 -51.893 -35.408 -18.451
Cash From Operating Activities -13.331 -50.139 -37.29 -27.993 -12.866
Amortization 0.791 3.18 2.39 1.6 0.78
Non-Cash Items 8.967 7.079 13.861 8.062 3.792
Changes in Working Capital 1.726 -3.602 -1.648 -2.247 1.013
Cash From Investing Activities 0 0 0 0
Other Investing Cash Flow Items, Total 0 0 0 0
Cash From Financing Activities 0.583 59.051 58.635 0.424 -0.166
Financing Cash Flow Items 0 -0.407 -0.407 -0.407 -0.407
Issuance (Retirement) of Stock, Net 0.583 59.458 59.042 0.831 0.241
Foreign Exchange Effects 0.015 -0.309 -0.365 -0.229 -0.035
Net Change in Cash -12.733 8.603 20.98 -27.798 -13.067
Capital Expenditures
Deferred Taxes 0

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Mind Medicine (MindMed) Company profile

Mind Medicine (MindMed) Inc is a biopharmaceutical company that develops clinical-stage psychedelic medicines to treat brain health disorders. The New York-based firm specialises in psychiatry, addiction, pain management and neurology.

Founded in May 2019, MindMed has several drug candidates targeting serotonin, dopamine and acetylcholine systems. These products are based on psychedelic and empathogen substances. The company’s main drug candidate is MM-120, which is a proprietary, pharmaceutically optimised form of LSD. The medication is being developed to treat generalised anxiety disorder (GAD). MindMed is also researching the drug in various dosing regimens for the treatment of attention deficit hyperactivity disorder, also known as attention-deficit/hyperactivity disorder (ADHD), as well as chronic pain.

MM-110, the company’s second advanced drug, is being developed to treat opioid withdrawal. The MM-110, also known by the non-proprietary name zolunicant, is a form of 18-methoxycoronaridine, an ibogaine congener.

The company’s third medicine candidate is MM-402, or R(-)-MDMA, a proprietary form of the R-enantiomer of MDMA (3,4-methylenedioxymethamphetamine). The medicine is being developed for the treatment of core symptoms of autism spectrum disorder.

In addition to its advanced stage drugs, the company also has several earlier stage research programmes through external collaboration, including a multi-year exclusive partnership with University Hospital Basel (UHB) in Switzerland.

MindMed does not own or operate any manufacturing facilities. All clinical and non-clinical materials are supplied by third-party contract manufacturing organisations, or CMOs.

MindMed went public on 27 February 2020 on the Toronto-based NEO Exchange under the ticker ‘MMED’. It is listed on Nasdaq under the symbol ‘MNMD’ and in Germany under the ticker ‘BGHM’.

Industry: Biotechnology & Medical Research (NEC)

1166 Alberni Steet
Suite 1604
VANCOUVER
BRITISH COLUMBIA V6E 3Z3
CA

Income Statement

  • Annual
  • Quarterly

News

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

Cable coils near lows ahead of Fed and BoE rate decisions

It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

14:16, 19 September 2023

FTSE 100 Technical Outlook - 18 September 2023

In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

06:55, 19 September 2023
View of the City of London’s illuminated financial district skyline at dusk

Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally

The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.

13:46, 15 September 2023

People also watch

XRP/USD

0.52 Price
+0.910% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01192

US100

14,733.50 Price
+0.390% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 21:00 (UTC)
Spread 1.8

ETH/USD

1,596.76 Price
+0.400% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 5.40

BTC/USD

26,690.70 Price
+0.190% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 85.00

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading